Page last updated: 2024-09-05

sorafenib and bilirubin

sorafenib has been researched along with bilirubin in 25 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(bilirubin)
Trials
(bilirubin)
Recent Studies (post-2010) (bilirubin)
6,5207305,25125,9211,3375,871

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)bilirubin (IC50)
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)3.3884
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)1.3183

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's17 (68.00)24.3611
2020's8 (32.00)2.80

Authors

AuthorsStudies
Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V1
Abbas, H; Bancelin, N; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Ropert, S; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M1
Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D1
Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R1
Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR; Sasanuma, H1
Agrogiannis, G; Chatziioannou, AN; Fokas, D; Kavatzas, N; Kostomitsopoulos, NG; Loxas, D; Malagari, K; Siskos, AP; Tamvakopoulos, C; Tsigkou, O1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O1
Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D1
Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT1
Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C1
Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP1
Chao, Y; Chen, YT; Hou, MC; Huang, YH; Huo, TI; Lee, FY; Lee, MH; Lee, PC; Li, CP; Lin, HC; Su, CW1
Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH1
Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K1
Kang, MK; Lee, HJ; Park, JG1
Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Tanaka, J; Toyoda, H; Tsuji, K1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, IH; Lin, ZY; Tsai, YS; Yeh, ML; Yu, ML1
Berhane, S; Bettinger, D; Blanc, JF; Bonnett, LJ; Cucchetti, A; De Man, RA; Edeline, J; Eskens, FALM; Johnson, PJ; Klümpen, HJ; Labeur, TA; Meyer, T; Takkenberg, RB; Ten Cate, DWG; Van Delden, OM; Van Vugt, JLA1
Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Muto, H1
Bargellini, I; Benito, A; Gebauer, B; Iezzi, R; Ingrisch, M; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Peynircioglu, B; Ricke, J; Seidensticker, M; Sengel, C; Ümütlü, MR; van Delden, O; Vandecaveye, V; Zech, CJ1
Fidan, E; Fidan, S; Kazaz, N; Merev, E1
Kuwano, A; Masumoto, A; Morita, Y; Motomura, K; Nagasawa, S; Tanaka, K; Yada, M1
Chen, J; Ding, X; Li, L; Li, W; Li, X; Zhang, Y1
Ang, C; Balcar, L; Bettinger, D; Cammarota, A; Cheon, J; Chon, HJ; Cortellini, A; D'Alessio, A; Fulgenzi, CAM; Gaillard, VE; Galle, PR; Huang, YH; Kudo, M; Marron, TU; Masi, G; Napolitano, A; Naqash, AR; Nishida, N; Personeni, N; Phen, S; Pinato, DJ; Pinter, M; Pressiani, T; Rimassa, L; Saeed, A; Salani, F; Scheiner, B; Schönlein, M; Schulze, K; Sharma, R; Singal, AG; Vivaldi, C; Vogel, A; von Felden, J; Wege, H; Wietharn, B; Wu, L1
Aratake, Y; Harada, S; Higuchi, N; Hioki, T; Kohjima, M; Koyanagi, T; Kuniyoshi, M; Kuwano, A; Morita, Y; Motomura, K; Mutsuki, T; Nagasawa, S; Nakamura, T; Nakamuta, M; Nakashima, M; Ooe, M; Ooho, A; Satoh, T; Senju, T; Sugimoto, R; Tada, S; Tanaka, K; Tanaka, M; Tanaka, Y; Uchimura, K; Ueda, A; Yada, M; Yamashita, N; Yoshimoto, T1

Reviews

1 review(s) available for sorafenib and bilirubin

ArticleYear
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.
    BMC cancer, 2022, Jul-09, Volume: 22, Issue:1

    Topics: Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib

2022

Trials

4 trial(s) available for sorafenib and bilirubin

ArticleYear
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
    Journal of hepatology, 2012, Volume: 56, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Aspartate Aminotransferases; Benzenesulfonates; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2012
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome

2015
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib

2017
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
    British journal of cancer, 2022, Volume: 126, Issue:2

    Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Prognosis; Sorafenib; Tumor Burden

2022

Other Studies

20 other study(ies) available for sorafenib and bilirubin

ArticleYear
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Transplantation, 2010, Jul-15, Volume: 90, Issue:1

    Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2010
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
    Pharmaceutical research, 2011, Volume: 28, Issue:12

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Female; Humans; Male; Neoplasms; Niacinamide; Orosomucoid; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Serum Albumin; Sorafenib; Young Adult

2011
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9

2012
Sorafenib inhibits liver regeneration in rats.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2013, Volume: 15, Issue:12

    Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Body Weight; Cell Proliferation; Hepatectomy; Ki-67 Antigen; Liver; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib; Time Factors

2013
Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
    Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:11

    Topics: Alanine Transaminase; Angiogenesis Inhibitors; Animals; Bilirubin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Ethiodized Oil; Feasibility Studies; gamma-Glutamyltransferase; Hepatic Artery; Liver; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tandem Mass Spectrometry

2013
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Analysis; United Kingdom; Young Adult

2016
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
    Biochemical pharmacology, 2017, 04-01, Volume: 129

    Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides

2017
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib

2017
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:12

    Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Failure

2017
Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:2

    Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Reproducibility of Results; Retreatment; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Treatment Failure

2018
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease-Free Survival; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin, Human; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom

2017
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Medicine, 2018, Volume: 97, Issue:17

    Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome

2018
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:6

    Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; ROC Curve; Serum Albumin, Human; Sorafenib; Survival Rate; Time Factors

2019
The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment.
    The Kaohsiung journal of medical sciences, 2019, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Prognosis; Sorafenib

2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:1

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Survival Analysis

2020
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.
    Medicine, 2021, Aug-06, Volume: 100, Issue:31

    Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Hepatocellular; Correlation of Data; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Japan; Liver; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Phenylurea Compounds; Quinolines; Serum Albumin; Sorafenib

2021
The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
    Nigerian journal of clinical practice, 2022, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Young Adult

2022
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Sorafenib

2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 175

    Topics: Albumins; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Sorafenib; Venous Thrombosis

2022
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
    Internal medicine (Tokyo, Japan), 2022, Volume: 61, Issue:21

    Topics: alpha-Fetoproteins; Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Sorafenib

2022